pancreatic cancer, pancreatic benign disease (chronic pancreatitis, IPMN) pancreatic cancer, exosome
Conditions
Interventions
None listed
Sponsors
Nana Shimamoto
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Individuals who was diagnosed with pancreatic cancer and untreated. (2) Individuals who attend the hospital under the diagnosis of the benign pancreatic disease. (3)Individuals who did not have a pancreatic cancer or the benign pancreatic tumor and visit Jikei medical chekup center. (4) Individuals aged 20 and over.
Exclusion criteria
Exclusion criteria: (1) Individuals who declined to participate in the research. (2) Individuals who are pregnant.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Difference in the amount of exosomes at the baseline among the pancreatic cancer, benign pancreatic disease and healthy control. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) Difference in the change in exosome levels before and after chemotherapy between the chemotherapy responsive and non-responsive groups. 2) Quantitative evaluation of the difference in exosome protein immunohistochemical staining (IHC) of FNA and surgical specimens between the chemotherapy responsive and non-responsive groups. 3) Difference in the exosome level compared at the baseline and at the reccurence. | — |
Contacts
Public ContactShimamoto Nana
The Jikei University School of Medicine
Outcome results
None listed